Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Am J Ther. 2024 Jul-Aug;31(4):e453-e455. doi: 10.1097/MJT.0000000000001666. Epub 2024 Feb 2.

Authors

Akhilesh Babbili¹, Rachaita Lakra¹, Sahith Reddy Thotamgari², Shiva Jashwanth Gaddam³, Udhayvir Singh Grewal⁴, Paari Dominic⁵

Affiliations

¹ Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA.
² Division of Cardiology, Louisiana State University Health Sciences Center, Shreveport, LA.
³ Division of Hematology and Oncology, Louisiana State University Health Sciences Center, Shreveport, LA.
⁴ University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA.
⁵ Division of Cardiology, University of Iowa Hospitals and Clinics, Iowa City, IA.

PMID: 38305826
DOI: 10.1097/MJT.0000000000001666

No abstract available

Publication types

Letter
Comparative Study

MeSH terms

Adenine* / adverse effects
Adenine* / analogs & derivatives
Aged
Atrial Fibrillation* / drug therapy
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / complications
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Male
Middle Aged
Piperidines* / adverse effects
Piperidines* / therapeutic use
Pyrazoles* / adverse effects
Pyrazoles* / therapeutic use
Pyrimidines* / administration & dosage
Pyrimidines* / adverse effects
Pyrimidines* / therapeutic use
Risk Assessment / methods

Substances

ibrutinib
Piperidines
Adenine
Pyrazoles
Pyrimidines